Bellicum Pharmaceuticals, an early-stage biotech developing controllable cancer immunotherapies, raised $140 million by offering 7.35 million shares (vs. 6.25 originally planned) at $19, above its $15 to $17 range. Bellicum will list on the NASDAQ under the symbol BLCM. Jefferies, Citi and Piper Jaffray acted as joint bookrunners on the deal.
